80.22 USD
-0.26 (-0.32%)
At close: Feb 10, 2026
80.22 USD
0 (0%)
After Hours: 2/10/2026, 8:12:12 PM
We assign a fundamental rating of 7 out of 10 to HALO. HALO was compared to 523 industry peers in the Biotechnology industry. While HALO has a great profitability rating, there are some minor concerns on its financial health. HALO is growing strongly while it also seems undervalued. This is an interesting combination These ratings would make HALO suitable for value and growth investing!
1. Profitability
1.1 Basic Checks
- In the past year HALO was profitable.
- In the past year HALO had a positive cash flow from operations.
- In the past 5 years HALO has always been profitable.
- Each year in the past 5 years HALO had a positive operating cash flow.
1.2 Ratios
- HALO has a better Return On Assets (26.81%) than 97.71% of its industry peers.
- Looking at the Return On Equity, with a value of 118.17%, HALO belongs to the top of the industry, outperforming 99.62% of the companies in the same industry.
- Looking at the Return On Invested Capital, with a value of 42.77%, HALO belongs to the top of the industry, outperforming 99.24% of the companies in the same industry.
- The Average Return On Invested Capital over the past 3 years for HALO is in line with the industry average of 18.27%.
- The last Return On Invested Capital (42.77%) for HALO is above the 3 year average (17.81%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 26.81% | ||
| ROE | 118.17% | ||
| ROIC | 42.77% |
ROA(3y)16.25%
ROA(5y)21.49%
ROE(3y)192.36%
ROE(5y)173.4%
ROIC(3y)17.81%
ROIC(5y)29.79%
1.3 Margins
- With an excellent Profit Margin value of 47.91%, HALO belongs to the best of the industry, outperforming 98.28% of the companies in the same industry.
- HALO's Profit Margin has declined in the last couple of years.
- With an excellent Operating Margin value of 59.33%, HALO belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
- In the last couple of years the Operating Margin of HALO has declined.
- Looking at the Gross Margin, with a value of 84.55%, HALO belongs to the top of the industry, outperforming 87.19% of the companies in the same industry.
- HALO's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 59.33% | ||
| PM (TTM) | 47.91% | ||
| GM | 84.55% |
OM growth 3Y-4.44%
OM growth 5YN/A
PM growth 3Y-21.62%
PM growth 5YN/A
GM growth 3Y1.07%
GM growth 5Y1.9%
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so HALO is creating value.
- The number of shares outstanding for HALO has been reduced compared to 1 year ago.
- HALO has less shares outstanding than it did 5 years ago.
- Compared to 1 year ago, HALO has an improved debt to assets ratio.
2.2 Solvency
- An Altman-Z score of 5.53 indicates that HALO is not in any danger for bankruptcy at the moment.
- With a decent Altman-Z score value of 5.53, HALO is doing good in the industry, outperforming 73.61% of the companies in the same industry.
- HALO has a debt to FCF ratio of 2.51. This is a good value and a sign of high solvency as HALO would need 2.51 years to pay back of all of its debts.
- HALO's Debt to FCF ratio of 2.51 is amongst the best of the industry. HALO outperforms 92.93% of its industry peers.
- A Debt/Equity ratio of 1.59 is on the high side and indicates that HALO has dependencies on debt financing.
- HALO has a worse Debt to Equity ratio (1.59) than 76.86% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.59 | ||
| Debt/FCF | 2.51 | ||
| Altman-Z | 5.53 |
ROIC/WACC3.65
WACC11.71%
2.3 Liquidity
- HALO has a Current Ratio of 1.59. This is a normal value and indicates that HALO is financially healthy and should not expect problems in meeting its short term obligations.
- Looking at the Current ratio, with a value of 1.59, HALO is doing worse than 79.54% of the companies in the same industry.
- HALO has a Quick Ratio of 1.37. This is a normal value and indicates that HALO is financially healthy and should not expect problems in meeting its short term obligations.
- With a Quick ratio value of 1.37, HALO is not doing good in the industry: 80.69% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.59 | ||
| Quick Ratio | 1.37 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 48.55% over the past year.
- HALO shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 30.12% yearly.
- HALO shows a strong growth in Revenue. In the last year, the Revenue has grown by 31.19%.
- Measured over the past years, HALO shows a very strong growth in Revenue. The Revenue has been growing by 38.95% on average per year.
EPS 1Y (TTM)48.55%
EPS 3Y30.12%
EPS 5YN/A
EPS Q2Q%35.43%
Revenue 1Y (TTM)31.19%
Revenue growth 3Y31.82%
Revenue growth 5Y38.95%
Sales Q2Q%22.12%
3.2 Future
- The Earnings Per Share is expected to grow by 17.78% on average over the next years. This is quite good.
- The Revenue is expected to grow by 13.23% on average over the next years. This is quite good.
EPS Next Y58.04%
EPS Next 2Y40.36%
EPS Next 3Y32.57%
EPS Next 5Y17.78%
Revenue Next Year38.12%
Revenue Next 2Y32.39%
Revenue Next 3Y25.48%
Revenue Next 5Y13.23%
3.3 Evolution
- Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
- The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
- A Price/Earnings ratio of 14.25 indicates a correct valuation of HALO.
- Compared to the rest of the industry, the Price/Earnings ratio of HALO indicates a rather cheap valuation: HALO is cheaper than 96.37% of the companies listed in the same industry.
- HALO's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 28.03.
- With a Price/Forward Earnings ratio of 9.63, the valuation of HALO can be described as very reasonable.
- Based on the Price/Forward Earnings ratio, HALO is valued cheaper than 98.09% of the companies in the same industry.
- The average S&P500 Price/Forward Earnings ratio is at 27.97. HALO is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.25 | ||
| Fwd PE | 9.63 |
4.2 Price Multiples
- Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of HALO indicates a rather cheap valuation: HALO is cheaper than 96.37% of the companies listed in the same industry.
- 96.94% of the companies in the same industry are more expensive than HALO, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 15.66 | ||
| EV/EBITDA | 12.16 |
4.3 Compensation for Growth
- The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- HALO has an outstanding profitability rating, which may justify a higher PE ratio.
- A more expensive valuation may be justified as HALO's earnings are expected to grow with 32.57% in the coming years.
PEG (NY)0.25
PEG (5Y)N/A
EPS Next 2Y40.36%
EPS Next 3Y32.57%
5. Dividend
5.1 Amount
- HALO does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
80.22
-0.26 (-0.32%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-03 2025-11-03/amc
Earnings (Next)02-24 2026-02-24/amc
Inst Owners105.85%
Inst Owner Change-1.53%
Ins Owners0.81%
Ins Owner Change-0.62%
Market Cap9.43B
Revenue(TTM)1.24B
Net Income(TTM)595.49M
Analysts76
Price Target79.56 (-0.82%)
Short Float %11.69%
Short Ratio6.66
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.41%
Min EPS beat(2)3.56%
Max EPS beat(2)19.26%
EPS beat(4)4
Avg EPS beat(4)11.06%
Min EPS beat(4)3.56%
Max EPS beat(4)19.26%
EPS beat(8)7
Avg EPS beat(8)12.2%
EPS beat(12)10
Avg EPS beat(12)9.54%
EPS beat(16)13
Avg EPS beat(16)9.68%
Revenue beat(2)2
Avg Revenue beat(2)6.93%
Min Revenue beat(2)2.18%
Max Revenue beat(2)11.69%
Revenue beat(4)4
Avg Revenue beat(4)7.01%
Min Revenue beat(4)1.36%
Max Revenue beat(4)12.81%
Revenue beat(8)6
Avg Revenue beat(8)5.71%
Revenue beat(12)7
Avg Revenue beat(12)2.94%
Revenue beat(16)9
Avg Revenue beat(16)2.47%
PT rev (1m)2.63%
PT rev (3m)3.08%
EPS NQ rev (1m)14.96%
EPS NQ rev (3m)13.89%
EPS NY rev (1m)4.46%
EPS NY rev (3m)6.45%
Revenue NQ rev (1m)10.99%
Revenue NQ rev (3m)11.2%
Revenue NY rev (1m)3.21%
Revenue NY rev (3m)5.06%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.25 | ||
| Fwd PE | 9.63 | ||
| P/S | 7.59 | ||
| P/FCF | 15.66 | ||
| P/OCF | 15.44 | ||
| P/B | 18.72 | ||
| P/tB | N/A | ||
| EV/EBITDA | 12.16 |
EPS(TTM)5.63
EY7.02%
EPS(NY)8.33
Fwd EY10.39%
FCF(TTM)5.12
FCFY6.39%
OCF(TTM)5.2
OCFY6.48%
SpS10.57
BVpS4.28
TBVpS-2.22
PEG (NY)0.25
PEG (5Y)N/A
Graham Number23.3
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 26.81% | ||
| ROE | 118.17% | ||
| ROCE | 53.28% | ||
| ROIC | 42.77% | ||
| ROICexc | 86.79% | ||
| ROICexgc | N/A | ||
| OM | 59.33% | ||
| PM (TTM) | 47.91% | ||
| GM | 84.55% | ||
| FCFM | 48.47% |
ROA(3y)16.25%
ROA(5y)21.49%
ROE(3y)192.36%
ROE(5y)173.4%
ROIC(3y)17.81%
ROIC(5y)29.79%
ROICexc(3y)23.94%
ROICexc(5y)N/A
ROICexgc(3y)71.73%
ROICexgc(5y)N/A
ROCE(3y)22.19%
ROCE(5y)37.11%
ROICexgc growth 3Y-1.13%
ROICexgc growth 5YN/A
ROICexc growth 3Y-28.16%
ROICexc growth 5YN/A
OM growth 3Y-4.44%
OM growth 5YN/A
PM growth 3Y-21.62%
PM growth 5YN/A
GM growth 3Y1.07%
GM growth 5Y1.9%
F-Score8
Asset Turnover0.56
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.59 | ||
| Debt/FCF | 2.51 | ||
| Debt/EBITDA | 0.98 | ||
| Cap/Depr | 10.51% | ||
| Cap/Sales | 0.69% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 74.59% | ||
| Profit Quality | 101.16% | ||
| Current Ratio | 1.59 | ||
| Quick Ratio | 1.37 | ||
| Altman-Z | 5.53 |
F-Score8
WACC11.71%
ROIC/WACC3.65
Cap/Depr(3y)13.62%
Cap/Depr(5y)33.32%
Cap/Sales(3y)1.21%
Cap/Sales(5y)0.98%
Profit Quality(3y)118.15%
Profit Quality(5y)93.9%
High Growth Momentum
Growth
EPS 1Y (TTM)48.55%
EPS 3Y30.12%
EPS 5YN/A
EPS Q2Q%35.43%
EPS Next Y58.04%
EPS Next 2Y40.36%
EPS Next 3Y32.57%
EPS Next 5Y17.78%
Revenue 1Y (TTM)31.19%
Revenue growth 3Y31.82%
Revenue growth 5Y38.95%
Sales Q2Q%22.12%
Revenue Next Year38.12%
Revenue Next 2Y32.39%
Revenue Next 3Y25.48%
Revenue Next 5Y13.23%
EBIT growth 1Y54.59%
EBIT growth 3Y25.97%
EBIT growth 5YN/A
EBIT Next Year61.82%
EBIT Next 3Y38.38%
EBIT Next 5Y15.57%
FCF growth 1Y70.36%
FCF growth 3Y16.28%
FCF growth 5YN/A
OCF growth 1Y65.76%
OCF growth 3Y16.96%
OCF growth 5YN/A
HALOZYME THERAPEUTICS INC / HALO FAQ
Can you provide the ChartMill fundamental rating for HALOZYME THERAPEUTICS INC?
ChartMill assigns a fundamental rating of 7 / 10 to HALO.
Can you provide the valuation status for HALOZYME THERAPEUTICS INC?
ChartMill assigns a valuation rating of 9 / 10 to HALOZYME THERAPEUTICS INC (HALO). This can be considered as Undervalued.
Can you provide the profitability details for HALOZYME THERAPEUTICS INC?
HALOZYME THERAPEUTICS INC (HALO) has a profitability rating of 8 / 10.
What is the financial health of HALOZYME THERAPEUTICS INC (HALO) stock?
The financial health rating of HALOZYME THERAPEUTICS INC (HALO) is 6 / 10.
Can you provide the expected EPS growth for HALO stock?
The Earnings per Share (EPS) of HALOZYME THERAPEUTICS INC (HALO) is expected to grow by 58.04% in the next year.